Fungicidal compositions

Abstract

Disclosed is a fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and the use of these compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

Description

[0001] The present application relates to novel fungicidal compositions, to their use in agriculture or horticulture for controlling diseases caused by phytopathogens, especially by phytopathogenic fungi, and to methods of controlling diseases on useful plants.

[0002] Certain oxadiazole derivatives are known, e.g., from CN 1927860, as insecticides and acaricides. The use of substituted oxadiazoles for combating phytopathogenic fungi is described in WO 2013 / 064079, EP 0 276 432 and WO 2015 / 185485.

[0003] Despite the fact that many fungicidal compounds and compositions belonging to a large number of different chemical classes have been developed or are being developed for use as fungicides in crops of useful plants, in many respects crop tolerance and activity against specific phytopathogenic fungi do not always meet the needs of agricultural practice. Thus, there is a continuous need to find new compounds and compositions having superior biological properties for controlling or preventing infestation of plants by phytopathogenic fungi. For example, compounds with greater biological activity, a favorable activity spectrum, increased safety profile, improved physico-chemical properties, or increased biodegradability. Or else, compositions with a broader activity spectrum, improved crop plant tolerance, improved synergistic interactions or enhanced properties, or which show a more rapid onset of action or have a longer lasting residual activity or enable a reduction in the number of applications and / or in the application rate of the compounds and compositions needed for effective control of phytopathogens, thus enabling beneficial resistance management practices, reducing environmental impact and decreasing exposure to operating personnel.

[0004] The use of compositions comprising mixtures of different fungicidal compounds having different modes of action can address some of these needs (e.g., by combining fungicides having different activity spectra).

[0005] According to the present application, there is provided a fungicidal composition comprising, as active ingredients, a mixture of components (A) and (B), wherein

[0006] Component (A) is a compound of formula (I):

[0007]

[0008] wherein

[0009] R 1 is hydrogen, -C(=0)CH3or -C(=0)CH2CH3,

[0010] R 2 is methyl or isopropyl, and

[0011] R3 is hydrogen or fluorine,

[0012] or a salt, enantiomer, tautomer, or N-oxide thereof; and

[0013] Component (B) is a compound selected from the group consisting of N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or a salt, enantiomer, tautomer, or N-oxide thereof.

[0014] Typically, the weight ratio of component (A) to component (B) can be from 100:1 to 1:100, preferably from 50:1 to 1:50, more preferably from 20:1 to 1:40, even more preferably from 15:1 to 1:30, still more preferably from 12:1 to 1:25, or from 10:1 to 1:20, or from 10:1 to 1:10, or from 5:1 to 1:15, or from 5:1 to 1:5, or from 4:1 to 1:4, or from 3:1 to 1:10, or from 3:1 to 1:3, or from 2:1 to 1:5, or 1:1.

[0015] In addition, according to the present invention, a method for controlling or preventing plant pathogenic diseases, especially plant pathogenic fungi, on useful plants or their propagation material is provided, the method comprising applying a fungicidal composition according to the present invention to such useful plants, their sites or their propagation material.

[0016] The benefits provided by certain fungicidal mixture compositions according to the invention may also include, in particular, favorable levels of bioactivity for protecting plants against fungal diseases or superior properties for use as an agrochemical active ingredient (e.g., greater bioactivity, favorable activity spectrum, increased safety, improved physicochemical properties, or increased biodegradability).

[0017] In a composition according to the invention, component (A) is a compound having formula (Ia):

[0018]

[0019] Where R 1 It is hydrogen, -C(=O)CH3 or -C(=O)CH2CH3.

[0020] Or its salts, enantiomers, tautomers or N-oxides.

[0021] In another composition according to the invention, component (A) is a compound having formula (Ib):

[0022]

[0023] Where R 1 It is hydrogen, -C(=O)CH3 or -C(=O)CH2CH3.

[0024] Or its salts, enantiomers, tautomers or N-oxides.

[0025] Preferably, component (A) is a compound selected from compounds A.01, A.02, A.03, A.04, A.05, A.06 and A.07 as defined in Table A below.

[0026] Table A

[0027]

[0028]

[0029] The presence of one or more possible asymmetric carbon atoms in component (B) means that the compound can exist in optical isomeric forms, i.e., enantiomers or diastereomers. As a result of restricted rotation around single bonds, turn-blocked isomers may also exist. This invention includes all those possible isomeric forms (e.g., geometric isomers) of component (B) and mixtures thereof. This invention includes all possible tautomeric forms of component (B) and also includes racemic compounds, i.e., mixtures of at least two enantiomers in a substantially 50:50 ratio.

[0030] In each case, the component (B) according to the invention is in free form, oxidized form such as N-oxide, or salt form (e.g., in the form of an agronomically available salt).

[0031] N-oxides are the oxidized forms of tertiary amines or nitrogen-containing heteroaromatic compounds. For example, they are described by A. Albini and S. Pietra in their 1991 book, "Heterocyclic N-oxides," published by CRC Press in Boca Raton.

[0032] Component (B) is a compound selected from compounds B.01, B.02, B.03, B.04, B.05, B.06, B.07, B.08, B.09, B.10, B.11, B.12, B.13, B.14 and B.15 as defined in Table B below.

[0033] Table B

[0034]

[0035]

[0036]

[0037] The presence of an asymmetric carbon atom in any of the compounds B.01, B.02, B.03, B.04, B.05, B.06, B.07, B.08, B.09, B.10, B.11, B.12, B.13, B.14, or B.15 as defined in Table B above means that these compounds may exist in chiral enantiomers, i.e., (R)- and (S)-enantiomers.

[0038] The final compound, which is pure in the enantiomeric sense, can be obtained, when appropriate, from racemic starting material via standard physical separation techniques (e.g., reversed-phase chiral chromatography) or via stereoselective synthesis techniques (e.g., using chiral starting material).

[0039] The preferred embodiments E.01 to E.105 listed in Table C below relate to binary mixtures, wherein the weight ratio of component (A) to component (B) can be from 100:1 to 1:100, preferably from 50:1 to 1:50, more preferably from 20:1 to 1:40, even more preferably from 15:1 to 1:30, still more preferably from 12:1 to 1:25, or from 10:1 to 1:20, or from 10:1 to 1:10, or from 5:1 to 1:15, or from 5:1 to 1:5, or from 4:1 to 1:4, or from 3:1 to 1:10, or from 3:1 to 1:3, or from 2:1 to 1:5, or 1:1.

[0040] Table C :

[0041]

[0042]

[0043] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O1), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-ethyl -2-Methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl) -[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

[0044] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propionate (A.O2), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl) (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

[0045] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.O3), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl) (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

[0046] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O4), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl Propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

[0047] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-acetoxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O5), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] ... [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol- 5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

[0048] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.06), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] ...[5-[trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methoxy-N-[[4-[5-[trifluoromethyl)- [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol- 5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

[0049] In the preferred composition according to the invention, component (A) is [(1R,2R)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propanoyloxy-pyridin-2-carbonyl)amino]propionate (A.07), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl) (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

[0050] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O1), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-ethyl -2-Methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl) -[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10.

[0051] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propionate (A.O2), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl) (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10.

[0052] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.O3), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl) (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10.

[0053] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O4), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl Propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10.

[0054] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-acetoxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O5), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] ... [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol- 5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10.

[0055] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.06), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] ...[5-[trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methoxy-N-[[4-[5-[trifluoromethyl)- [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol- 5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10.

[0056] In the preferred composition according to the invention, component (A) is [(1R,2R)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propanoyloxy-pyridin-2-carbonyl)amino]propionate (A.07), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5-yl) (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10.

[0057] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O1), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-ethyl 2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 5:1 to 1:5.

[0058] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propionate (A.O2), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 5:1 to 1:5.

[0059] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.O3), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 5:1 to 1:5.

[0060] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O4), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl Propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 5:1 to 1:5.

[0061] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-acetoxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.05), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 5:1 to 1:5.

[0062] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridin-2-carbonyl)amino]propionate (A.06), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 5:1 to 1:5.

[0063] In the preferred composition according to the invention, component (A) is [(1R,2R)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propanoyloxy-pyridin-2-carbonyl)amino]propionate (A.07), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 5:1 to 1:5.

[0064] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O1), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-ethyl 2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 4:1 to 1:4.

[0065] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propionate (A.O2), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 4:1 to 1:4.

[0066] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.O3), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 4:1 to 1:4.

[0067] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O4), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl Propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 4:1 to 1:4.

[0068] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-acetoxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.05), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 4:1 to 1:4.

[0069] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridin-2-carbonyl)amino]propionate (A.06), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 4:1 to 1:4.

[0070] In the preferred composition according to the invention, component (A) is [(1R,2R)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propanoyloxy-pyridin-2-carbonyl)amino]propionate (A.07), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 4:1 to 1:4.

[0071] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O1), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-ethyl 2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 3:1 to 1:3.

[0072] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propionate (A.O2), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 3:1 to 1:3.

[0073] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.O3), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 3:1 to 1:3.

[0074] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O4), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl Propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 3:1 to 1:3.

[0075] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-acetoxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.05), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 3:1 to 1:3.

[0076] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridin-2-carbonyl)amino]propionate (A.06), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 3:1 to 1:3.

[0077] In the preferred composition according to the invention, component (A) is [(1R,2R)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propanoyloxy-pyridin-2-carbonyl)amino]propionate (A.07), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 3:1 to 1:3.

[0078] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O1), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-ethyl 2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] Propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1:2.

[0079] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propionate (A.O2), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1:2.

[0080] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.O3), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1:2.

[0081] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O4), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl Propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [Phenylene]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1:2.

[0082] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-acetoxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.05), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1:2.

[0083] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridin-2-carbonyl)amino]propionate (A.06), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazole] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1:2.

[0084] In the preferred composition according to the invention, component (A) is [(1R,2R)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propanoyloxy-pyridin-2-carbonyl)amino]propionate (A.07), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] [4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazol-5- (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1:2.

[0085] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-hydroxy-4-methoxy-pyridine-2-carbonyl)amino]propionate (A.O1), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N- Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]phenyl] [Methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazolidine] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is 1:1.

[0086] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propionate (A.O2), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]phenyl] [[4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazolidine] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is 1:1.

[0087] In the preferred composition according to the invention, component (A) is [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridin-2-carbonyl)amino]propionate (A.O3), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]phenyl] [[4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazolidine] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is 1:1.

[0088] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-hydroxy-4-methoxy-pyridin-2-carbonyl)amino]propionate (A.O4), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] ... [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea [-yl]phenyl]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methyl] (5-methyl-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, and ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylate, or salts, enantiomers, tautomers, or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is 1:1.

[0089] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]propionate (A.O5), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea 3-yl]phenyl]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methyl] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is 1:1.

[0090] In the preferred composition according to the invention, component (A) is [(1S,2S)-2-(4-fluoro-2-methyl-phenyl)-1,3-dimethyl-butyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.06), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] [Methyl]propionamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea 3-yl]phenyl]methyl]propionamide, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methyl] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is 1:1.

[0091] In the preferred composition according to the invention, component (A) is [(1R,2R)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridin-2-carbonyl)amino]propionate (A.07), or a salt, enantiomer, tautomer, or N-oxide thereof, and component (B) is selected from the group consisting of: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]phenyl] [[4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidine-3-one, 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine, (3-methylisoxazolidine] (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] ketone, 2-oxo-N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide and 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylic acid ethyl ester, or salts, enantiomers, tautomers or N-oxides thereof, wherein the weight ratio of component (A) to component (B) is 1:1.

[0092] In any of the compositions according to the invention, the composition may contain an additional active ingredient component (C) that is different from component (B) and is selected from the group consisting of: metyltetrapole, azoxystrobin, oxadiazon, pyraclostrobin, pyraclostrobin, fenoxystrobin, prothioconazole, cyclophosphamide, difenoconazole, tebuconazole, propiconazole, flutriafol, hexaconazole, chlorfluazon, tebuconazole, benzo[a]fluoroquinolones, fluopyram, fluopyram, fluopyram, cyclophosphamide, bifenazate, pyraclostrobin, fluopyram, fluopyram, isoflucypram, inpyrfluxam, quinofumelin, ipflufenoquin, aminopyrimethanil fen, fluazinam, fludioxamid, fenpicoxamid, pyridoxin, benzyl benzoate, butyl morpholine, mancozeb, chlorothalonil, trifluoropyridine, Cu-chloride, Cu-hydroxide, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidinium), N'-[5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidinium, N'-[5-bromo-2-methyl-6-[(1R ... -6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidinium, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidinium, N'-(2-chloro-5-methyl-4-phenoxyphenyl)-N-ethyl-N-methyl-formamidinium, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methyl-formamidinium, N'-[2-chloro-4-(3-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methyl-formamidinium, N'-(2-bromo-5-methyl-4-phenoxyphenyl)-N-ethyl-N-methyl-formamidinium, N'-[2- [bromo-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidinium, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-isopropyl-N-methylformamidinium, N'-[4-(2-cyanophenoxy)-2-methyl-5-(trifluoromethyl)phenyl]-N-ethyl-N-methylformamidinium, N'-[5-bromo-2-methyl-4-(2-methylphenoxy)phenyl]-N-ethyl-N-methylformamidinium, N-ethyl-N'-[4-(2-fluorophenoxy)-2-methyl-5-(trifluoromethyl)phenyl]-N-methylformamidinium, (Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-Dimethyl-pent-3-enamine, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamine, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thio-4H-1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile, 3-[(4-chlorophenyl)methyl]-2-hydroxy-1-methyl-2-(1, 2,4-Triazol-1-ylmethyl)cyclopentanecarboxylate, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)prop-2-ol, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)prop-2-ol, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]thiobenzamide, N-methyl-4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, N-[N-methoxy-C-methyl-carbonimide]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol- [3-yl]benzamide, N-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]cyclopropaneformamide, N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, 1-(5,6-dimethyl-3-pyridyl)-4,4-difluoro-3,3-dimethyl-isoquinoline, and 1-[6-(difluoromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-isoquinoline.

[0093] Preferably, component (C), which differs from component (B), is a compound selected from the group consisting of: metyltetrapole, azoxystrobin, oxadiazon, azoxystrobin, phenoxybenzonitr, prothioconazole, cyclophosphamide, difenoconazole, tebuconazole, propiconazole, chlorfluazon, tebuconazole, benzo[a]fluoroquinolones, fluopyram, fluopyram, pyraclostrobin, inpyrfluxam, fluazinam, pyridabenamide, benzyl benzoate, mancozeb, chlorothalonil, trifluoropyridamole, Cu-chloride, Cu-hydroxide, N'-[5-bromo-2-methyl-6-(1-)-[2-(2-)-[2-)-[2-] ... [5-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidin, N'-[5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidin, N'-[5-bromo-2-methyl-6-[(1R)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidin and N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidin.

[0094] These component (C) compounds are referred to in this text and above by the so-called "ISO common name" or another "common name" or trademark name used in individual cases. Component (C) compounds are known and commercially available and / or can be prepared using procedures known in the art and / or procedures reported in the literature, such as WO 2015 / 155075 and WO 2016 / 202742, WO 2017 / 005710, WO 2018 / 108977, WO 2018 / 153707, WO 2018 / 098216, WO 2019 / 093522, WO 2018 / 145921, WO 2015 / 185485, WO 2017 / 076742, WO 2017 / 081311, WO 2017 / 085100, WO 2017 / 093019, WO 2017 / 178245 and WO 2017 / 211649.

[0095] In embodiments of the present invention, the composition comprises component (A), component (B), and component (C), wherein the weight ratio of component (A) to the sum of components (B) and (C) may be from 100:1 to 1:100, preferably from 50:1 to 1:50, more preferably from 20:1 to 1:40, even more preferably from 15:1 to 1:30, still more preferably from 12:1 to 1:25, or from 10:1 to 1:20, or from 10:1 to 1:10, or from 5:1 to 1:15, or from 5:1 to 1:5, or from 4:1 to 1:4, or from 3:1 to 1:10, or from 3:1 to 1:3, or from 2:1 to 1:5, or 1:1.

[0096] As used herein, the term "fungicide" refers to a compound that controls, alters, or prevents the growth of fungi. The term "effective fungicide amount" refers to the amount of one or a combination of such compounds that can affect fungal growth. Controlling or altering effects include all deviations from natural development, such as killing, inhibiting, etc., and prevention includes the formation of barriers or other defenses within or on the plant to prevent fungal infection.

[0097] The term "plant" refers to all the tangible parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, culms, leaves, and fruits.

[0098] The term "plant propagation material" refers to all reproductive parts of a plant, such as seeds or vegetative parts like cuttings and tubers. It includes seeds in the strict sense, as well as roots, fruits, tubers, bulbs, rhizomes, and other parts of the plant.

[0099] As used herein, the term "site" means the place in which or on which a plant grows, or the place where the seeds of a cultivated plant are sown, or the place where the seeds will be placed in the soil. It includes soil, seeds, and seedlings, along with the established vegetation.

[0100] Throughout this document, the term "composition" refers to different mixtures or combinations of components (A) and (B) (including the embodiments defined above), for example, in a single "ready-to-use with water" form, as a combined spray mixture (consisting of individual formulations of these single active ingredient components) (e.g., a "tank mix"), and as a combination of these single active ingredients when applied in a sequential manner (i.e., one after the other after a suitable short period, such as hours or days). For the purposes of this invention, the order in which components (A) and (B) are applied is not critical.

[0101] The compositions according to the present invention are effective against harmful microorganisms (such as microorganisms) that cause plant pathogenic diseases, especially against plant pathogenic fungi and bacteria.

[0102] The compositions of the present invention can be used to control plant diseases caused by a broad spectrum of fungal plant pathogens belonging to the Basidiomycetes, Ascomycetes, Oomycetes and / or Deuteromycetes, Blastodactycetes, Chrytidiomycetes, Glomeromycetes and / or Mucoromycetes.

[0103] This composition effectively controls a broad spectrum of plant diseases, such as leaf pathogens in ornamental plants, turf, vegetables, fields, cereals, and fruit crops.

[0104] These pathogens may include:

[0105] Oomycetes include Phytophthora diseases, such as those caused by *Phytophthora capsici*, *Phytophthora causalosa*, *Phytophthora soybeani*, *Phytophthora fragariae*, *Phytophthora nicotianae*, *Phytophthora cinnamomi*, *Phytophthora citricola*, *Phytophthora citrophthora*, and *Phytophthora erythroseptica*; Pythium diseases, such as those caused by *Pythium cucurbitae*, *Pythium arrhenomanes*, *Pythium gracilis*, *Pythium irregulare*, and *Pythium tertruncatum*; and Downycetes, such as those caused by *Peronospora destructor*, *Peronospora cabbage*, *Peronospora grapei*, *Peronospora sunfloweri*, *Peronospora cucumberi*, and *Albugo*. Diseases caused by *Candida*, rice downy mildew, and lettuce downy mildew; as well as others, such as those caused by *Sclerospora graminicola*, *Labyrinthula zosterae*, *Peronosclerospora sorghi*, and *Sclerospora graminicola*.

[0106] Ascomycetes, including diseases such as spot, blight, wilt, or downy mildew and / or rot, such as those caused by the following: *Stemphylium solani* (garlic white spot fungus), *Stagonosporatainanensis* (Tainan daffodil), *Setosphaeria turcica* (corn large leaf spot fungus), *Pyrenochaeta lycoperisici* (tomato bark fungus), *Stemphylium solani* (leaf rot fungus), *Phoma destructiva* (stem rot fungus), *Phaeosphaeria herpotrichoides* (wheat leaf dark spot fungus), *Phaeocryptocus gaeumannii* (brown cryptococcus), *Ophiosphaerella graminicola* (grass rot fungus), *Ophiobolus graminis* (wheat take-all fungus), *Leptosphaeria maculans* (cruciferous small spore fungus), *Hendersonia creberrima* (soft rot fungus), *Helminthosporium* (leaf blight fungus). Triticirepentis, Setosphaeria turcica (corn leaf spot pathogen), Drechslera glycines (soybean hymenopterus), Didymella bryoniae (watermelon vine blight pathogen), Cycloconium oleagineum (olive leaf spot pathogen), Corynespora cassiicola, Bipolaris cactivora (dragon fruit black spot pathogen), Apple black spot pathogen, Pyrenophora tritici-repentis (oat sclerotium), Alternaria brassicicola (alternaria brassicicola), Alternaria solanacea (solanum alternaria), and Alternaria tomatophila (tomatophila); Capnodiales such as Septoriaglycines (wheat spores), Septoriaglycines (soybean spores), and Cercospora (peanut causal agent). arachidicola), soybean gray spot fungus, corn gray spot fungus, capsella bursa-pastoris fungus, wheat white mold fungus (Cercosporella capsellae), wheat leaf mold fungus (Cercosporella herpotrichoides), peach scab fungus (Cladosporium carpophilum), sparse cladoceran (Cladosporium effusum), and brown mold (Passalora).* *Fructus fulva*, *Cladosporium oxysporum*, *Dothistromaseptosporum*, *Isariopsis clavispora*, *Pseudocercospora vitis*, *Mycovellosiella koepkeii*, *Phaeoisariopsis bataticola*, *Pseudocercospora vitis*, *Wheat basal rot*, *Begonia leaf spot*, *Ramularia collo-cygni*; *Metacarpaceae* such as *Tricholoma spp.*, *Magnaporthe grisea*, *Pyrrosia spp.*; *Metacarpaceae* such as *Fusarium wilt east of hazelnut*, *Apiognomonia errabunda*, *Cytospora*. platani), soybean northern stem canker fungus, *Discula destructiva*, strawberry scab (*Gnomonia fructicola*), grape bitter rot fungus, walnut black scab (*Melanconium juglandinum*), grape viticola (*Phomopsis viticola*), walnut canker fungus (*Sirococcus clavigignenti-juglandacearum*), *Tubakia dryina*, *Dicarpella* species, apple tree rot fungus (*Valsa ceratosperma*); and others, such as *Actinothyrium graminis*, pea pod spores, *Aspergillus flavus*, *Aspergillus fumigatus*, *Aspergillus nidus*, *Pachyphytum comosum*, leaf spot fungus (*Blumeriella jaapii*), *Candida* species, sooty mold fungus (*Capnodium*). ramosum), species of the genus *Cephaloascus* spp., *Cephalosporium gramineum*, *Ceratocystis paradoxa*, species of the genus *Chaetoceros*, *Hymenoscyphus pseudoalbidus*, species of the genus *Coccidioides*, *Cylindrosporium padi*, *Diplocarpon malae*, *Drepanopeziza**Campestris*, *Elsinoe ampelina*, *Coccus niger*, *Epidermophytes* species, grape top blight, *Geotrichum candida*, *Gibellina cerealis*, *Gloeocercospora sorghi*, *Gloeodes pomigena*, *Gloeosporium perennans*; endophytic fungi of dead wheat (Gloeotinia temulenta), *Griphospaeria corticola*, *Kabatiella lini*, *Leptographium microsporum*, *Leptosphaerulinia crassiasca*, *Lophodermium seditiosum*, *Marssonina graminicola*, *Microdochium nivale*, *Monilinia* (Australian type of brown rot fungus). fructicola), rice cloud-shaped disease (Monographella albescens), melon black spot root rot fungus (Monosporascus cannonballus), species of the genus *Naemacyclus* spp., new elm wilt fungus (Ophiostoma novo-ulmi), *Paracoccidioides brasiliensis*, *Penicillium expansum*, *Pestalotia rhododendri*, species of the genus *Petriellidium* spp., species of the genus *Pezicula* spp., soybean stem brown rot fungus (Phialophora gregata), pome fruit black spot fungus (Phyllachorapomigena), omnivorous hornworm (Phymatotrichum omnivora), cryptocystis (Physalospora abdita), tobacco cyst shell (Plectosporium) *Taccacidium*, *Polyscytalumpustulans*, *Pseudopeziza medicaginis*, *Pyrenopeziza brassicae*, *Ramulispora**Rhabdoclinepseudotsugae*, *Rhynchosporium secalis*, *Sacrocladium oryzae*, *Scedosporium spp.*, *Schizothyrium pomi*, *Sclerotinia sclerotiorum*, *Sclerotinia minor*; *Sclerotium spp.*, *Typhula ishikariensis*, *Seimatosporium mariae*, *Lepteutypa cupressi*, *Septocyta ruborum*, *Sphaceloma perseae*, *Sporonemaphacidioides*, *Stigmina* Palmivora, Tapesiayallundae, Taphrina bullata, Thielviopsis basicola, Trichoseptoria fructigena, Zygophialajamaicensis; powdery mildew, for example, caused by Powdery Mildew fungi such as wheat powdery mildew, Polygonum powdery mildew, Grape powdery mildew, Cucumber powdery mildew (Sphaerotheca fuligena), White-forked powdery mildew, Podospaera macularis, Two-spore powdery mildew (Golovinomyces cichoracearum), Tartary powdery mildew (Leveillula taurica), Spreading powdery mildew, Oidiopsis gossypii, Phylactinia guttata, and Oidium arachifolium. Those caused by *Arachidis*; molds, such as those caused by *Botryotinia* species like *Dothiorella aromatica*, *Diplodia seriata*, *Guignardia bidwellii*, *Botrytis cinerea*, *Botryotinia allii*, and *Botryotinia spp.*Those caused by *Fabae*, *Fusicoccum amygdali*, *Lasiodiplodia theobromae*, *Macrophoma theicola*, *Coccidioidomyces chinensis*, and *Phyllosticta cucurbitacearum*; anthracnose, such as those caused by *Glommerelales* species like *Colletotrichum lagenarium*, *Colletotrichum lagenarium*, *Anthracnose spp.*, *Glommerelales*, and *Anthracnose gracilis*; and wilt or blight, such as those caused by *Hylocereus* species like *Atoporhynchus stenoptera*, *Eroxystrobinus purpureus*, *Fusarium graminearum*, *Fusarium graminearum*, *Fusarium oxysporum* f. sp. *cubense*, and *Gerlachia nigricans*. Those caused by *Gnaphalium affine*, *Gnaphalium zeylanum*, *Gnaphalium rubrum*, *Gnaphalium*, *Gnaphalium verum*, *Gnaphalium ramulariae*, *Trichoderma viride*, *Gnaphalium pinkum*, and *Verticillium theobromae*;

[0107] Basidiomycetes include diseases such as smut caused by smut fungi such as *Ustilaginoidea virens*, *Ustilago nuda*, *Ustilago tritici*, and *Ustilago zeae*, and rust diseases caused by stalk rust fungi such as *Cerotelium fici*, *Chrysomyxa arctostaphyli*, *Coleosporium ipomoeae*, *Hemileia vastatrix*, *Puccinia arachidis*, *Puccinia cacabata*, *Puccinia graminis*, *Puccinia recondita*, *Puccinia sorghi*, *Puccinia hordei*, and *Puccinia striiformis*. f.sp.Hordei), Puccinia striiformisf.sp.Those caused by *Secalis*, *Pucciniastrum coryli*; or those caused by *Ruscidea* species such as *Cronartium ribicola*, *Gymnosporangium juniperi-viginianae*, *Melampsora medusae*, *Phakopsora pachyrhizi*, *Phragmidium mucronatum*, *Physopella ampelosidis*, *Tranzschelia discolor*, and *Uromyces viciae-fabae*; and other rots and diseases, such as those caused by *Cryptococcus* species, *Exobasidium vexans*, *Marasmiellus inoderma*, *Sphagnum* species, and *Sphacelotheca*. Those caused by *Sclerotium reiliana*, *Typhula ishikariensis*, *Urocystis agropyri*, *Itersonilia perplexans*, *Corticium invisum*, *Laetisaria fuciformis*, *Waitea circinata*, *Rhizoctonia solani*, *Thanetephorus cucurmeris*, *Entyloma dahliae*, *Entylomella microspora*, *Neovossia moliniae*, and *Tilletia caries*.

[0108] Cladosporidioides, such as Physoderma maydis;

[0109] Mucormycetes, such as *Choanephora cucurbitarum*; species of the genus *Mucor*; *Rhizopus*; and diseases caused by other species and genera closely related to those listed above.

[0110] In addition to their antifungal activity, these compositions may also have activity against bacteria such as *Pyrus pyrifolia*, *Erwinia caratovora*, *Xanthomonas laurentii*, *Pseudomonas syringae*, *Strptomyces scabies*, and other related species, along with certain protozoa.

[0111] The compositions according to the invention are particularly effective against plant pathogenic fungi belonging to the following classes: Ascomycetes (e.g., *Aureobasidium*, *Cyclocarya*, *Erythrophagus*, *Cyclocarya*, *Cyclocarya*, *Uncaria*); Basidiomycetes (e.g., *Hemileia*, *Rhizoctonia*, *Laminaria*, *Pterygophyllum*, *Ustilago*, *Ustilago*); Deuteromycetes (also known as Deuteromycetes, e.g., *Botrytis*, *Helicobacter*, *Rhizophora*, *Fusarium*, *Syndrome*, *Cercospora*, *Alternaria*, *Pyrophora*, and *Pseudocercospora*); Oomycetes (e.g., *Phytophthora*, *Peronospora*, *Pseudorhyx*, *Euphorbia*, *Plasmodium*, *Pythium*, *Pseudocercospora*, *Monocospora*).

[0112] The compositions according to the invention can be used in useful plant crops including perennial and annual crops, such as berry plants, such as blackberries, blueberries, cranberries, raspberries, and strawberries; cereals, such as barley, corn, millet, oats, rice, rye, sorghum, triticale, and wheat; fiber plants, such as cotton, flax, hemp, jute, and sisal; field crops, such as sugar beets and forage beets, coffee beans, hops, mustard, rapeseed (canola), poppies, sugarcane, sunflowers, tea, and tobacco; fruit trees, such as apples, apricots, avocados, bananas, cherries, citrus fruits, nectarines, peaches, pears, and plums; and grasses, such as Bermuda grass, bluegrass, benjamin grass, centipede grass, yew grass, ryegrass, and sage grass. Stinging grass and zoysia grass; herbs such as basil, borage, chives, coriander, lavender, angelica, mint, oregano, parsley, rosemary, sage, and thyme; legumes such as kidney beans, lentils, peas, and soybeans; nuts such as almonds, cashews, peanuts, hazelnuts, peanuts, pecans, pistachios, and walnuts; palm trees such as oil palms; ornamental plants such as flowers, shrubs, and trees; other trees such as cacao, coconut, olive, and rubber trees; vegetables such as asparagus, eggplant, broccoli, cabbage, carrots, cucumbers, garlic, lettuce, zucchini, melons, okra, onions, peppers, potatoes, squash, rhubarb, spinach, and tomatoes; and grapevines such as grapes.

[0113] Crops should be understood as those that exist naturally, are obtained through conventional breeding methods, or are obtained through genetic engineering. These include crops that possess so-called output traits (such as improved storage stability, higher nutritional value, and improved flavor).

[0114] Crops should be understood to include those that have been conferred tolerance to herbicides (like bromufenoxam) or multiple classes of herbicides (such as ALS-, EPSPS-, GS-, HPPD-, and PPO- inhibitors). Examples of crops that have been conferred tolerance to imidazolinones (e.g., methoxyfenozide) through conventional breeding methods are... Summer Canola. Examples of crops conferred herbicide tolerance through genetic engineering include, for example, glyphosate and glufosinate-resistant maize varieties, which are marketed under trademarks... Herculex and It is available for commercial purchase.

[0115] Crops should also be understood to be those that are naturally or have been conferred resistance to pests. This includes plants that, for example, are capable of synthesizing one or more selectively acting toxins through the use of recombinant DNA technology, such toxins as those known from toxin-producing bacteria. Examples of toxins that can be expressed include delta-endotoxins, vegetative insecticidal proteins (Vip), insecticidal proteins from bacterial colonizing nematodes, and toxins produced by scorpions, arachnids, wasps, and fungi.

[0116] An example of a crop that has been modified to express Bacillus thuringiensis toxin is Bt maize. (Syngenta Seeds). Examples include crops that encode insecticidal resistance and thereby express more than one gene for more than one toxin. (Syngenta Seeds). Crops or their seed material can also be resistant to multiple types of pests (so-called superimposed transgenic events when produced through genetic modification). For example, plants can express insecticidal proteins while being resistant to herbicides, such as Herculex. (Dow AgroSciences, Pioneer Hi-Bred International)

[0117] The fungicidal composition according to the present invention can be used to control or prevent plant pathogenic diseases, especially plant pathogenic fungi (e.g., strychnos rutinus) on soybean plants.

[0118] Specifically, transgenic soybean plants expressing toxins such as insecticidal proteins like delta-endotoxins (e.g., Cry1Ac (Cry1Ac Bt protein)). Therefore, this can include transgenic soybean plants containing event MON87701 (see U.S. Patent No. 8,049,071 and related applications and patents, and WO 2014 / 170327 A1 (see, for example, regarding Intacta RR2PRO)). TM The paragraph on soybeans

[008] ), event MON87751 (U.S. Patent Application Publication No. 2014 / 0373191) or event DAS-81419 (U.S. Patent No. 8632978 and related applications and patents).

[0119] Other transgenic soybean plants may include the following: SYHT0H2-HPPD tolerance (US Patent Application Publication No. 2014 / 0201860 and related applications and patents), MON89788-glyphosate tolerance (US Patent No. 7,632,985 and related applications and patents), MON87708-dicamba tolerance (US Patent Application Publication No. US 2011 / 0067134 and related applications and patents), DP-356043-5-glyphosate and ALS tolerance (US Patent Application Publication No. US 2010 / 0184079 and related applications and patents), A2704-12-glufosinate tolerance (US Patent Application Publication No. US 2008 / 0320616 and related applications and patents), and DP-305423-1-ALS tolerance (US Patent Application Publication No. US 2011 / 0067134 and related applications and patents). The following events were involved: Event A5547-127-glufosinate tolerance (US Patent Application Publication No. US 2008 / 0312082 and related applications and patents); Event DAS-40278-9-tolerance to 2,4-dichlorophenoxyacetic acid and aryloxyphenoxypropionate (see WO2011 / 022469, WO 2011 / 022470, WO 2011 / 022471 and related applications and patents); Event 127-ALS tolerance (WO 2010 / 080829 and related applications and patents); Event GTS. 40-3-2-glyphosate tolerance, event DAS-68416-4-2,4-dichlorophenoxyacetic acid and glufosinate tolerance, event FG72-glyphosate and isoxaflutole tolerance, event BPS-CV127-9-ALS tolerance and GU262-glufosinate tolerance or event SYHT04R-HPPD tolerance.

[0120] The fungicidal compositions according to the invention can be used to control or prevent plant pathogenic diseases, particularly plant pathogenic fungi (e.g., *Solanum spp.*) on soybean plants. In particular, certain superior soybean varieties are known in the scientific literature to have R gene stacks conferring some degree of immunity or resistance to specific *Solanum spp.* species infiltrated into the plant genome; see, for example, “Fighting Asian Soybean Rust”, Langenbach C et al., Front Plant Science 7(797) 2016.

[0121] Superior plants are any plants that come from superior strains; therefore, superior plants are representative plants that come from superior varieties. Non-restricted examples of commercially available superior soybean varieties for farmers or soybean breeders include: AG00802, A0868, AG0902, A1923, AG2403, A2824, A3704, A4324, A5404, AG5903, AG6202, AG0934; AG1435; AG2031; AG2035; AG2433; AG2733; AG2933; AG3334; AG3832; AG4135; AG4632; AG4934; AG5831; AG6534; and AG7231 (Asgrow Seeds, Des Moines, Iowa, USA); BPR0144RR, BPR 4077NRR, and BPR 4390NRR (Bio Botanical Institute). Plant Research, Camp Point, Illinois, USA; DKB17-51 and DKB37-51 (DeKalb Genetics, DeKalb, Illinois, USA); DP 4546RR and DP 7870RR (Delta & Pine Land Company, Lubbock, Texas, USA); JG03R501, JG 32R606C ADD and JG 55R503C (JGL Inc.).), Greencastle, Indiana, USA); NKS 13-K2 (NK Division of Syngenta Seeds, Golden Valley, Minnesota, USA); 90M01, 91M30, 92M33, 93M11, 94M30, 95M30, 97B52, P008T22R2; P16T17R2; P22T69R; P25T51R; P34T07R2; P35T58R; P39T67R; P47T36R; P46T21R; and P56T03R2 (Pioneer Seeds International Ltd.) Hi-Bred International, Johnston, Iowa, USA; SG4771NRR and SG5161NRR / STS (Soygenetics, LLC, Lafayette, Indiana, USA); S00-K5, S11-L2, S28-Y2, S43-B1, S53-A1, S76-L9, S78-G6, S0009-M2; S00 7-Y4; S04-D3; S14-A6; S20-T6; S21-M7; S26-P3; S28-N6; S30-V6; S35-C3; S36-Y6; S39-C4; S47-K5; S48-D9; S52-Y2; S58-Z4; S67-R6; S73-S8; and S78-G6 (Syngenta Seeds, Henderson, Kentucky, USA); Richer (Northstar Seed Ltd., Alberta, Canada); 14RD62 (Stine Seed Co., Iowa, USA); or Armor 4744 (Armor Seed, LLC, Alaska, USA).

[0122] Therefore, in another preferred embodiment, the fungicidal composition according to the invention is used to control *Phyllostachys spp.* rust (including its fungicide-resistant strains, as described below) on superior soybean plant varieties, wherein stacks of R genes conferring a certain degree of immunity or resistance to a particular *Phyllostachys spp.* rust have been infiltrated into the plant genome. Numerous benefits can be anticipated from this use, such as improved bioactivity, a favorable or broader spectrum of activity (including susceptible and resistant strains of *Phyllostachys spp.* rust), increased safety, improved crop tolerance, synergistic interactions or enhancing properties, improved onset or longer persistent residual activity, reduced application frequency and / or lower application rate of the compounds and compositions required for effective control of the plant pathogen (*Phyllostachys spp.* rust), thereby achieving beneficial resistance-management practices, reduced environmental impact, and reduced operator exposure.

[0123] In certain circumstances, the fungicidal compositions according to the invention may exhibit synergistic interactions between active ingredients when used to control or prevent plant pathogenic diseases, particularly plant pathogenic fungi (such as *Potamogeton crispus*) on soybean plants (especially any genetically modified soybean plants as described above).

[0124] The fungicidal composition according to the present invention can be used to control or prevent plant pathogenic diseases, especially plant pathogenic fungi (particularly strychnoides rust) on soybean plants.

[0125] In addition, to date, no cross-resistance has been observed between component (B) (including any of compounds B.01 to B.15) and current fungicidal solutions used to control rust fungi in the potato layer.

[0126] In fact, fungicide-resistant strains of Phakopsora pachyrhizi have been reported in the scientific literature, in which strains resistant to one or more fungicides from at least each of the following fungicidal action modes: sterol demethylation inhibitors (DMI), quinone outside inhibitors (QoI), and succinate dehydrogenase inhibitors (SDHI). See, for example: “Sensitivity of Phakopsora pachyrhizi towards quinone-outside-inhibitors and demethylation-inhibitors, and corresponding resistance mechanisms.” Schmitz HK et al., Pest Management Sci (2014) 70:378-388; “First detection of a SDH variant with reduced SDHI sensitivity in Phakopsora pachyrhizi”. K et al., J Plant Dis Prot (2018) 125:21-2; “Competitive fitness of Phakopsora pachyrhizi isolates with mutations in the CYP51 and CYTB genes.” Klosowski AC et al., Phytopathology (2016) 106:1278-1284; “Detection of the F129L mutation in the cytochrome b gene in Phakopsora pachyrhizi.” Klosowski AC et al., Pest Management Sci (2016) 72:1211-1215.

[0127] Therefore, in a preferred embodiment, the fungicidal composition according to the invention is used to control rust fungus in the potato layer, which is resistant to one or more fungicides from any of the following MoA class of fungicides: sterol demethylation inhibitor (DMI), quinone inhibitor (QoI), and succinate dehydrogenase inhibitor (SDHI).

[0128] The component (A) used according to the present invention can be prepared according to any synthesis technique described in WO 2019 / 173665.

[0129] The component (B) used according to the present invention can be prepared according to any of the synthesis techniques described in WO 2017 / 055469, WO 2017 / 055473, WO 2017 / 093348, WO 2017 / 118689, WO 2017 / 220485, WO 2018 / 065414, WO 2018 / 158365, WO 2018 / 177894, WO 2018 / 177880, WO 2018 / 219773 and WO 2019 / 002151.

[0130] It should be understood that, in an aqueous medium, component (B) according to the invention can exist in reversible equilibrium with its corresponding covalently hydrated form. This dynamic equilibrium may be important for the bioactivity of component (B).

[0131] The compositions of the present invention, including all the embodiments and preferred examples disclosed above, can be mixed with one or more other pest control agents, including additional fungicides, insecticides, nematicides, bactericides, acaricides, growth regulators, chemical sterilizers, chemical pheromones, insect repellents, attractants, pheromones, feeding stimulants, or other bioactive compounds to form multi-component pest control agents that provide broader-spectrum agricultural protection.

[0132] Examples of such agricultural protectants and the compositions of the present invention can be formulated as follows:

[0133] Fungicides such as tebuconazole, fluazinam, benzalkonium chloride, benzalkonium chloride-M (refined benzalkonium chloride), furazolidone, metalaxyl, metalaxyl-M (refined metalaxyl), doxycycline, N'-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidin, N'-[4-(4,5-dichloro-thiazol-2-yloxy)-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidin, N'-[4-[[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]oxy]-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidin, ethamsylate, 3'-chloro-2-methoxy-N-[(3RS)-tetrahydro-2 [-Oxyfuran-3-yl]acetyl-2',6'-dimethylaniline (clozylacon), pyrimethanil, azoxystrobin, pyrimethanil, dithionol, nystatin aureum, blast fungicide-S, biphenyl, dimethomorph, clonidium, benzo[a]fluoroquinolones, fluopyram, hexachlorobenzene, pentachloronitrobenzene, tetraoxonylnitrobenzene (TCNB), methyl thiophanate, benomyl, 2,6-dichloro-N-(4-trifluoromethylbenzyl)-benzamide, fluopicolide or flupicolide, thiocyanate benzamide, sulfadiazine, benomyl, carbendazim, carbendazim hydrochloride, clofenazole, thiamethoxam, thiabendazole, methyl thiophanate Benzyl thiamethoxam, cymoxanil, thiamethoxam, aramacin, basil, pyraclostrobin (IKF-309), aramacin-S-methyl, pyraclostrobin (KIF-7767), butylamine, 3-iodo-2-propynyl n-butylcarbamate (IPBC), iodopropynyl butylcarbamate (isopropyl butylcarbamate), isopropyl butylcarbamate (iodopropynyl butylcarbamate), piperazine, polycarbamate, cymoxanil, trifluoromethoxycarbamate, 3-(difluoromethyl)-N-(7-fluoro-1,1,3,3-tetramethyl-indan-4-yl)-1-methyl-pyrazole-4-carboxamide, dichloroisocyanurate, N-[(5-chloro-2-isopropyl) [-phenyl)methyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methylpyrazole-4-carboxamide, N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-[(2-isopropylphenyl)methyl]-1-methylpyrazole-4-carboxamide, cyclopropionylamine, chlorothalonil, flumorph, copper quinoline, cymoxanil, cyazofamid, cymoxanil, fluoxastrobin, thiamethoxam, ethoxysulfuron, iprodione, procymidone, ethirimol sulfonate, chlorpyrifos, nitrofen, chlorfenapyr, chlorfenapyr, diphenylamine, chlorfenapyr, 2,6-dimethyl-[1,4]dithiazoline[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-Tetraone, Thiram Oxide, Mancozeb, Ferrous Thiram, Mancozeb Zinc, Mancozeb, Mancozeb, Metiram or Polyram, Metiram-Zinc, Sodium Mancozeb, Methyl Mancozeb, Thiram, Verbam (Sodium Metiram), Mancozeb, Zinc Thiram, Dimethyl Disulfide, Isoprothiolane, Thiazolamide, Tris(ethylphosphonic acid), Phosetyl-Al (Aluminum Tris(ethylphosphonic acid)), Methyl Bromomethyl, Iodomethyl, Methyl Isothiocyanate, Cyclomethrin, Mefenoxam, Enteromycin, Streptomycin, (2RS)-2-Bromo-2-(Bromomethyl)Glutaronitrile (Bromomethyl) (Bactericides), Sodium thiosulfate, Dodecyl guanidine acetate, Biguanidine octyl salt, Biguanidine octylamine, Biguanidine octylamine triacetate, 2,4-D, 2,4-DB, Kasugamycin, Mefenoxam, Cyclomethrin, Hymexazol, Sodium thiosulfate, Imazalil, Enoxac, Oxadiazon, Isoprothiolane, Prochloraz, Fluopyram, Imidacloprid, Bordeaux mixture, Calcium polysulfide, Copper acetate, Copper carbonate, Copper hydroxide, Copper naphthenate, Copper oleate, Copper oxychloride, Copper hydroxyquinoline, Copper silicate, Copper sulfate, Copper fatty acid, Cuprous oxide, Sulfur, Carbaryl, Isoprothiolane (Tetrachlorophthalide), Pyrimethanil (Jun Siqi) SiQi), thiamethoxam, pyraclostrobin, dimethomorph, KSF-1002, phytohexidine, dimethomorph, butylmorpholine, tridemorpholine, dodecylmorpholine, ethoxysulfuron, triphenyltin acetate, triphenyltin hydroxide, carbendazim, oxycarbendazim, oxadiazon, m-phenylphenol, p-phenylphenol, tribromophenol (TBP), 2-[2-[(7,8-difluoro-2-methyl-3-quinolinyl)oxy]-6-fluoro-phenyl]propane-2-ol, 2-[2-fluoro-6-[(8-fluoro-2-methyl-3-quinolinyl)oxy]phenyl]propane-2-ol, cycloflufenicol, furazolidone, oxadixyl, fluopyram, cymoxanil, isothiazine), seed dressing, fludioxonil, pentazocide Long, Kefensan, Isoprothiolane, Pyridaben, Phosphate, Leaf blight phthalate, Captan, Captan, Mefenoxam, Azoxystrobin, Benzoyl, Powder-resistant agent, Osthol, 1-Methylcyclopropene, 4-CPA, Chlormequat chloride, Benaziridine, 2,4-D propionic acid, Thiamethoxam, Indomethacin, Ethephon, Flurazole, Chlorpyrifos, Gibberellin, Hymexazol, Maleic hydrazide, Tocopherol, Naphthylacetamide, Paclobutrazol, Cyclobutrazol-Calcium, Thiidon, Defoliant (Tributyl trithiophosphate), Anti-rot ester, Uniconazole, α-Naphthaleneacetic acid, Polyoxin D (Polyoxin Remo), BLAD, Chitosan, Isoprothiolane, Mefenoxam, 3-(Difluoromethyl)-N-methoxy-1-methyl-N-[1-methyl-2-(2,4,[6-Trichlorophenyl)ethyl]pyrazole-4-carboxamide, bifenthiophanate-methyl, fluopyram, furopyram, pyrazolenaphthylamine, pendimethalin, pyrimethanil, fluoxastrobin, acetamiprid, pyridaben, pyridaben, fluopyram, diflubenzuron, chloropyrimidinol, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine, pyrimethanil, dimetachlone, dimethaclone, iodoquinazon, ethoxyquin, quinoxaline, 4,4,5-trifluoro-3,3-dimethyl-1-(3-quinolinyl)isoquinoline, 4,4-difluoro-3,3-dimethyl-1-(3-quinolinyl)isoquinoline 5-Fluoro-3,3,4,4-Tetramethyl-1-(3-quinolinyl)isoquinoline, 9-Fluoro-2,2-dimethyl-5-(3-quinolinyl)-3H-1,4-benzoxazine, isobutylethoxyquinoline, oxaflutole, chinomethionate or oxythioquinox, quinoxymethionate, spirocycline, (E)-N-methyl-2-[2-(2,5-dimethylphenoxymethyl)phenyl]-2-methoxy-iminoacetamide, (mandesbin), azoxystrobin, eugenol, fenamidone, enoxastrobin, enoxastrobin Fenamistrobin), fluopyram, fluopyram, azoxystrobin, mandesbin, benzoxystrobin, pyraclostrobin, oxime azoxystrobin, azoxystrobin, pyraclostrobin, chlorpyrifos, azoxystrobin, indazole sulfadiazine, methamidophos, methamidophos, butyl-3-ynyl N-[6-[[(Z)-[(1-methyltetrazole-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate, dazomet, isothiazamide, thiamethoxam, thiamethoxam, thifluzamide, benzothiamethoxam (TCMTB), thiosilazine, benzoxystrobin, cymoxanil, tricyclazole, (.+-.)-cis-1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)-cycloheptanol (cycloheptanol), 1 -(5-bromo-2-pyridyl)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1,2,4-triazol-1-yl)prop-2-ol, 2-(1-tert-butyl)-1-(2-chlorophenyl)-3-(1,2,4-triazol-1-yl)prop-2-ol (TCDP), azaconazole, bifenthazole, furazolidone, clopyralid Cycloconazole, difenoconazole, dimethoprim, tebuconazole, tebuconazole-M, fluconazole, eticonazole, cyproconazole, fluquinazole, flusilazole, fenbendazole, hexaconazole, imidacloprid, isofenfluconazole, tebuconazole, cyproconazole, propiconazole, prothioconazole, siloxyfenazole, tebuconazole, tetraflufenazole, triadimefon, triadimefon, imidazolimum, cymoxanil, 2-[[(1R,5S)-5-[(4-fluorophenyl)methyl]-1-hydroxy-2,2-dimethyl-cyclopentyl]methyl]-4H-1,2,4-triazol-3-thione, 2-[[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)ethyleneoxy-2-yl]methyl]-4H-1,2,4-triazol-3-thione, imidium, zinc propineb, valachlor, 2-benzyl-4-chlorophenol (benzylchlorophenol), allyl alcohol, pyrazosulfuron, benzalkonium chloride, chloropicrin, cresol, daracide, diclofenac (dichlorophenol), oat meal, disulfiram, N-(2-p-chlorobenzoylethyl)-lead hexachloride, NNF-0721, octathione, pyrimisulfuron-methyl, propanemidine, and propionic acid.

[0134] Insecticides such as abamectin, chlorpyrifos, acetamiprid, sulfadiazine (S-1955), abamectin, azadirachtin, methyl glutathione, bifenthrin, bifenazate, thiamethoxam, carbofuran, batan, chlorantraniliprole (DPX-E2Y45), brofenoxam, flufenoxuron, chlorpyrifos, methyl chlorpyrifos, cyclone dichlorvos, thiamethoxam, diflubenzuron, lambda-cyhalothrin, β-cyhalothrin, and deltamethrin. λ-Cypermethrin, Cypermethrin, Cyromazine, Delmethrin, Difenoconazole, Diazinon, Dichlorvos, Diflubenzuron, Tetrafluthrin, Dimethoate, Fipronil, Benzyl ether, Emamectin, Endothiophanate-methyl, Cypermethrin, Ethylenenitrile, Benthiocarb, Fenoxycarb, Cypermethrin, Cypermethrin, Fipronil, Flupyradifurone, Flupyradifurone, T-Flumethrin, Pyrimethanil (UR-50701), Flufenoxuron, Terbufos, Chlorfenapyr Flufenoxam, flufenoxuron, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, cyfluthrin, metaldehyde, methamidophos, chlorpyrifos, methomyl, tebufenozide, methoxychloride, methoxybenzylflupyr, phosmet, methoxyfenozide, acetamiprid, nifedipine, diphenylfluorourea, polyfluorourea (XDE-007), chlorpyrifos, parathion, methyl parathion, permethrin, phorate, phosmet, phosmet, phosphamidon, pirimicarb, profenofos, propargite Pyrethroids, pymetrozine, pyrethroids, acetamiprid, flufenoxuron, pyriprole, fenproxen, rotenone, linanodin, spinosad, spinosad, spirodiclofen, spirodiclofen (BSN2060), spirotetramat, thiophanate-methyl, tebufenozide, flufenoxuron, pyrethroid, terbufos, carbendazim, thiamethoxam, thiamethoxam, thiamethoxam, chlorpyrifos, tetrabromopyr, pymetrozine, trichlorfon, and carbaryl;

[0135] Bactericides such as streptomycin;

[0136] Acaricides such as amitraz, dicofol, ethyl methacrylate, cypermethrin, tricyclic tin, trichlorfon, chlorpyrifos, etoxazole, quinclorac, fenbutatin, cypermethrin, pyridaben, thiamethoxam, dicofol, pyridaben, and pyridaben; and

[0137] Biological reagents such as Bacillus thuringiensis, Bacillus thuringiensis δ-endotoxin, baculoviruses, insect pathogens, bacteria, viruses, and fungi.

[0138] The compositions described above can be used in methods for controlling pests, which include applying a composition containing the mixture described above to the pest or its environment.

[0139] A mixture comprising components (B) selected from Table B (above) and one or more active ingredients as described above can be applied, for example, as a single "ready-to-use" solution, as a combined spray mixture (consisting of individual formulations of these single active ingredient components) (such as a "bucket mix"), and when applied in a sequential manner (i.e., one after another after a moderately short period, such as hours or days). The order in which the components (B) selected from Table B (above) and these active ingredients as described above are applied is not critical to the implementation of this invention.

[0140] These compositions of the present invention can also be used for crop enhancement. According to the present invention, 'crop enhancement' means improved plant vigor, improved plant quality, improved tolerance to stress factors, and / or improved input utilization efficiency.

[0141] According to the present invention, 'improvement of plant vigor' means that certain traits are improved in quality or quantity when compared with the same traits of control plants that have been grown under the same conditions but without using the method of the present invention. Such traits include, but are not limited to, earlier and / or improved germination, improved emergence, ability to use fewer seeds, increased root growth, more developed root system, increased root nodulation, increased bud growth, increased tillering, stronger tillering, more efficient tillering, increased or improved plant uprightness, less plant verse (lodging), increased and / or improved plant height, increased plant weight (fresh or dry weight), larger leaves, greener leaf color, increased pigment content, increased photosynthetic activity, earlier flowering, longer panicles, earlier grain maturity, increased seed, fruit, or pod size, increased number of pods or ears, increased number of seeds per pod or ear, increased seed quality, enhanced seed filling, fewer dead basal leaves, delayed wilting, improved plant vigor, increased levels of amino acid compounds in storage tissues, and / or the need for less input (e.g., less fertilizer, water, and / or labor required). Vitality-enhanced plants may have an increase in any of the above traits or any combination thereof, or in two or more of the above traits.

[0142] According to the present invention, 'improvement of plant quality' means that certain traits are improved in quality or quantity when compared with the same traits of control plants that have been grown under the same conditions but without using the method of the present invention. Such traits include, but are not limited to, improved visual appearance of plants, reduced ethylene (reduced production and / or inhibited reception), improved quality of harvested materials (e.g., seeds, fruits, leaves, vegetables) (such improved quality can manifest as improved visual appearance of harvested materials, improved carbohydrate content (e.g., increased sugar and / or starch content, improved sugar-acid ratio, reduced reducing sugars, increased rate of sugar formation), improved protein content, improved oil content and composition, improved nutritional value, reduced anti-nutritional compounds, improved sensory properties (e.g., improved taste) and / or improved consumer health benefits (e.g., increased vitamin and antioxidant levels)), improved post-harvest characteristics (e.g., enhanced shelf life and / or storage stability, easier processability, easier compound extraction), more uniform crop development (e.g., simultaneous germination, flowering, and / or fruiting of plants) and / or improved seed quality (e.g., for use in subsequent seasons). Quality-improved plants may have increases in any of these traits or any combination thereof, or in two or more of the aforementioned traits.

[0143] According to the present invention, improved tolerance to stress factors means that certain traits are qualitatively or quantitatively improved compared to the same traits in control plants under the same conditions lacking the method of the present invention. Such traits include, but are not limited to, increased tolerance and / or resistance to a variety of abiotic stress factors that induce suboptimal growth conditions, such as drought (e.g., any stress leading to a lack of plant water content, a lack of water absorption potential, or a reduction in water supply to the plant), cold, heat, osmotic stress, UV stress, flooding, increased salinity (e.g., salinity in the soil), increased mineral exposure, ozone exposure, high light exposure, and / or limited nutrient (e.g., nitrogen and / or phosphorus) utilization. Plants with improved tolerance to stress factors may have increases in any of the above-described traits or any combination thereof, or in two or more of the above-described traits. In the case of drought and nutrient stress, these improvements in tolerance may be attributed to, for example, more efficient absorption, utilization, or retention of water and nutrients.

[0144] According to the present invention, 'improved input utilization efficiency' means that a plant is able to use a given input level more efficiently than a control plant grown under the same conditions but without using the method of the present invention. Specifically, these inputs include, but are not limited to, fertilizers (such as nitrogen, phosphorus, potassium, and micronutrients), light, and water. Plants with improved input utilization efficiency may have improved use of any of the above-described inputs, or any combination of two or more of the above-described inputs.

[0145] Other crop enhancements of the present invention include reducing plant height or reducing tillering, which are beneficial features in crops or under conditions where less biomass and fewer tillers are desired.

[0146] Any or all of the above crop enhancements can result in improved yields by improving, for example, plant physiology, plant growth and development, and / or plant architecture. In the context of this invention, 'yield' includes, but is not limited to: (i) increases in biomass production, cereal yield, starch content, oil content, and / or protein content, which may result from: (a) an increase in the amount produced by the plant itself or (b) improved harvesting capacity of plant material, (ii) improvements in the composition of harvested material (e.g., improved sugar-acid ratio, improved oil composition, increased nutritional value, reduced anti-nutritional compounds, increased consumer health benefits) and / or (iii) increased / facilitated harvesting capacity of the crop, improved crop processability, and / or better storage stability / shelf life. Increased yield of agricultural plants means, where quantitative measurement is possible, a measurably greater yield of a particular product of a particular plant than the yield of the same product produced by that plant under the same conditions (but without the application of this invention). According to the invention, preferably, the yield increase is at least 0.5%, more preferably at least 1%, even more preferably at least 2%, still more preferably at least 4%, preferably 5%, or even more.

[0147] Any or more crop enhancements can also lead to land use improvements, meaning that land that was previously unusable or suboptimal for planting can become usable. For example, plants that show enhanced survival under drought conditions can be grown in areas with suboptimal rainfall (e.g., perhaps on the edge of a desert or even in the desert itself).

[0148] In one aspect of the invention, crop enhancement is achieved under conditions where stress from pests and / or diseases and / or abiotic stresses is substantially absent. In another aspect of the invention, improvements in plant vigor, stress tolerance, quality, and / or yield are achieved under conditions where stress from pests and / or diseases is substantially absent. For example, pests and / or diseases can be controlled by applying a pest-killing treatment before or simultaneously with the method of the invention. In yet another aspect of the invention, improvements in plant vigor, stress tolerance, quality, and / or yield are achieved under conditions where pest and / or disease stress is absent. In further embodiments, improvements in plant vigor, quality, and / or yield are achieved under conditions where abiotic stresses are absent or substantially absent.

[0149] These compositions of the present invention can also be used in the field of protecting stored goods from fungal attack. According to the invention, the term "stored goods" should be understood to refer to natural substances of plant and / or animal origin and their processed forms, derived from their natural life cycle and intended for long-term protection. Plant-derived stored goods (such as plants or parts thereof (e.g., stems, leaves, tubers, seeds, fruits, or grains)) can be protected in a freshly harvested state or in a processed form (e.g., pre-dried, moistened, crushed, ground, or baked). Also falling under the definition of stored goods is timber, whether in log form, such as building timber, transmission towers, and fences, or in the form of finished products, such as furniture or objects made from timber. Animal-derived stored goods are hides, leather, fur, hair, etc. The compositions according to the invention can prevent adverse effects such as decay, fading, or mold. Preferably, "stored goods" should be understood to refer to natural substances of plant origin and / or their processed forms, more preferably fruits and their processed forms (e.g., pome, stone fruit, berries, and citrus fruits and their processed forms). In another preferred embodiment of the invention, "stored goods" should be understood to mean timber.

[0150] Therefore, another aspect of the present invention is a method for protecting stored goods, the method comprising applying a composition according to the present invention to the stored goods.

[0151] The compositions of the present invention can also be used in the field of protecting technical materials from fungal attack. According to the present invention, the term "technical material" includes paper; blankets; buildings; cooling and heating systems; wall panels; ventilation and air conditioning systems, etc.; preferably, "technical material" should be understood to refer to wall panels. The compositions according to the present invention can prevent adverse effects such as decay, fading, or mold growth.

[0152] The compositions according to the invention are typically formulated in a variety of ways using formulation aids (such as carriers, solvents, and surfactants). These formulations can be in various physical forms, for example, as powders, gels, wettable powders, water-dispersible granules, water-dispersible tablets, effervescent compressed tablets, emulsifiable concentrates, microemulsifiable concentrates, oil-in-water emulsions, flowable oils, aqueous dispersions, oily dispersions, suspensions, capsule suspensions, emulsifiable granules, soluble liquids, water-soluble concentrates (with water or a water-miscible organic solvent as a carrier), impregnated polymer films, or in other known forms, such as those described in the Manual on Development and Use of FAO and WHO Specifications for Pesticides, United Nations, 1st Edition, Second Revision (2010). Such formulations can be used directly or diluted before use. It can be diluted with, for example, water, liquid fertilizer, micronutrients, biological organisms, oil or solvents.

[0153] These formulations can be prepared, for example, by mixing the active ingredients with formulation aids to obtain compositions in the form of finely dispersed solids, particles, solutions, dispersions, or emulsions. These active ingredients can also be formulated with other aids, such as finely dispersed solids, mineral oils, oils of plant or animal origin, modified oils of plant or animal origin, organic solvents, water, surfactants, or combinations thereof.

[0154] These active ingredients can also be encapsulated in microcapsules. Microcapsules contain the active ingredient within a porous carrier. This allows the active ingredient to be released into the environment in a controlled amount (e.g., slow release). Microcapsules typically have a diameter from 0.1 to 500 micrometers. The amount of active ingredient they contain is approximately 25% to 95% by weight of the capsule. These active ingredients can be in the form of a monolithic solid, fine particles in a solid or liquid dispersion, or in a form suitable for solution. The encapsulating membrane can contain, for example, natural or synthetic rubber, cellulose, styrene / butadiene copolymers, polyacrylonitrile, polyacrylates, polyesters, polyamides, polyureas, polyurethanes, or chemically modified polymers, as well as starch xanthates, or other polymers known to those skilled in the art. Alternatively, very fine microcapsules can be formed in which the active ingredient is contained in the form of finely dispersed particles within a solid matrix of the base material, but these microcapsules themselves are not encapsulated.

[0155] Formulation aids suitable for preparing formulations according to the present invention are known in themselves. As liquid carriers, the following can be used: water, toluene, xylene, petroleum ether, vegetable oil, acetone, methyl ethyl ketone, cyclohexanone, acid anhydride, acetonitrile, acetophenone, amyl acetate, 2-butanone, butenyl carbonate, chlorobenzene, cyclohexane, cyclohexanol, alkyl acetate, diacetone alcohol, 1,2-dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, N,N-dimethyl... Formamide, dimethyl sulfoxide, 1,4-dioxane, dipropylene glycol, dipropylene glycol methyl ether, dipropylene glycol dibenzoate, dipropylene glycol, alkylpyrrolidone, ethyl acetate, 2-ethylhexanol, ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, α-pinene, d-limonene, ethyl lactate, ethylene glycol, ethylene glycol butyl ether, ethylene glycol methyl ether, γ-butyrolactone, glycerol, glyceryl acetate, glyceryl diacetate, glyceryl triacetate, deca-acetate, etc. Hexadecane, hexanediol, isopentyl acetate, isobornyl acetate, isooctane, isophorone, cumene, isopropyl myristate, lactic acid, laurylamine, isopropyl acetone, methoxypropanol, methyl isopentyl ketone, methyl isobutyl ketone, methyl lauryl ketone, methyl octanoate, methyl oleate, dichloromethane, m-xylene, n-hexane, n-octylamine, octadecanoic acid, octylamine acetate, oleic acid, oleyleneamine, o-xylene, phenol, polyethylene glycol, propionic acid, propyl lactate Propylene carbonate, propylene glycol, propylene glycol methyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylenesulfonic acid, paraffin, mineral oil, trichloroethylene, perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, propylene glycol methyl ether, diethylene glycol methyl ether, methanol, ethanol, isopropanol, and alcohols with higher molecular weights, such as pentanol, tetrahydrofuranol, hexanol, octanol, ethylene glycol, propylene glycol, glycerol, N-methyl-2-pyrrolidone, etc.

[0156] Suitable solid carriers include, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, diatomaceous earth, limestone, calcium carbonate, bentonite, calcium montmorillonite, cottonseed hulls, wheat flour, soybean flour, pumice, wood flour, ground walnut shells, lignin, and similar substances.

[0157] Many surfactants can be advantageously used in both solid and liquid formulations, especially those that can be diluted with a carrier before use. Surfactants can be anionic, cationic, nonionic, or polymeric, and they can be used as emulsifiers, wetting agents, suspending agents, or for other purposes. Typical surfactants include, for example, salts of alkyl sulfates, such as diethanolammonium dodecyl sulfate; salts of alkyl aryl sulfonates, such as calcium dodecylbenzenesulfonate; alkylphenol / olefin oxide addition products, such as ethoxylated nonylphenol; alcohol / olefin oxide addition products, such as ethoxylated tridecyl alcohol; soaps, such as sodium stearate; salts of alkyl naphthalene sulfonates, such as sodium dibutylnaphthalene sulfonate; salts of dialkyl sulfosuccinates, such as sodium di(2-ethylhexyl)sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary ammonium, such as dodecyltrimethylammonium chloride; polyethylene glycol esters of fatty acids, such as polyethylene glycol stearate; block copolymers of ethylene oxide and propylene oxide; and salts of monoalkyl and dialkyl phosphate esters; and other substances, such as those described in McCutcheon's Detergents and Emulsifiers Annual, MC Publishing. Corp.), Ridgewood, New Jersey (1981).

[0158] Other adjuvants that can be used in formulations for killing pests include crystallization inhibitors, viscosity modifiers, suspending agents, dyes, antioxidants, foaming agents, light absorbers, mixing aids, defoamers, complexing agents, substances that neutralize or change pH and buffer solutions, corrosion inhibitors, fragrances, wetting agents, absorption enhancers, micronutrients, plasticizers, flow aids, lubricants, dispersants, thickeners, antifreeze agents, microbial agents, and liquid and solid fertilizers.

[0159] Formulations according to the invention may include additives comprising oils of vegetable or animal origin, mineral oils, alkyl esters of such oils, or mixtures of such oils with oil derivatives. The amount of oil additive in the formulations according to the invention is typically from 0.01% to 10% of the mixture to be applied. For example, the oil additive may be added to the spray can at the desired concentration after the spray mixture has been prepared. Preferred oil additives include mineral oils or vegetable oils, such as rapeseed oil, olive oil, or sunflower oil; emulsified vegetable oils; alkyl esters of vegetable oils, such as methyl derivatives; or animal oils, such as fish oil or tallow. Preferred oil additives include C8-C... 22 Alkyl esters of fatty acids, especially C 12 -C 18Methyl derivatives of fatty acids, such as lauric acid, palmitic acid, and methyl esters of oleic acid (methyl laurate, methyl palmitate, and methyl oleate, respectively). Many oil derivatives are known in the Compendium of Herbicide Adjuvants, 10th edition, Southern Illinois University, 2010.

[0160] These formulations typically contain, by weight, from 0.1% to 99%, particularly from 0.1% to 95% of the compounds of components (A) and (B), and by weight, from 1% to 99.9% of formulation aids, which preferably include, by weight, from 0% to 25% of surfactants. Commercial products may preferably be formulated as concentrates, while end users will typically use diluted formulations.

[0161] Application rates vary over a wide range and depend on soil properties, application method, crop species, pests to be controlled, primary climatic conditions, and other factors governed by application method, application time, and target crop. Generally, compounds can be applied at rates ranging from 1 l / ha to 2000 l / ha, particularly from 10 l / ha to 1000 l / ha.

[0162] Some of the compositions described above can exhibit synergistic effects. This synergistic effect occurs whenever the combined effect of the active ingredients exceeds the sum of the effects of the individual components. For a given combination of active ingredients, the expected effect E follows the so-called Colby formula and can be calculated as follows (COLBY, SR, "Calculating synergistic and antagonistic responses of herbicide combination," Weeds, Vol. 15, pp. 20-22; 1967):

[0163] ppm = the number of milligrams of active ingredient (=ai) per liter of spray mixture.

[0164] X = % effect of active ingredient (p ppm) calculated as active ingredient A),

[0165] Y = % effect of active ingredient (based on active ingredient B) using q ppm of active ingredient.

[0166] According to Colby, using active ingredients at p+q ppm, the expected effect of (additive) active ingredients A)+B) is:

[0167]

[0168] If the observed effect (O) is greater than the expected effect (E), then the combined effect is superadditive, i.e., a synergistic effect exists. Mathematically, a synergistic effect corresponds to a positive value of the difference (OE). In the case of purely complementary addition of the active ingredient (expected activity), the difference (OE) is zero. A negative value of the difference (OE) indicates a loss of activity compared to the expected activity.

[0169] However, in addition to the actual synergistic effect relative to the fungicidal activity, the compositions according to the invention may also have other unexpectedly advantageous properties. Examples of such advantageous properties that may be mentioned are: more favorable degradability; improved toxicological and / or ecotoxicological behavior; or improved characteristics of useful plants, including: emergence, crop yield, more developed root system, increased tillering, increased plant height, larger leaves, less basal leaf mortality, stronger tillering, greener leaf color, less fertilizer required, less seed required, more tillering, earlier flowering, earlier grain maturity, less lodging, enhanced bud growth, improved plant vigor, and earlier germination.

[0170] The compositions according to the invention can be applied to plant pathogenic microorganisms, useful plants, their sites, their propagation materials, stored goods, or technical materials threatened by microbial attack.

[0171] The composition according to the invention can be applied before or after useful plants, their propagation materials, stored goods or technical materials are infected by microorganisms.

[0172] The amount of the composition according to the invention to be applied will depend on various factors, such as the compound used; the object to be treated, such as plants, soil or seeds; the type of treatment, such as spraying, dusting or seed dressing; the purpose of the treatment, such as prevention or treatment; the type of fungus to be controlled or the timing of application.

[0173] When applied to beneficial plants, component (A) is typically applied in combination with component (B) at a ratio of 5 to 2000 g ai / ha, particularly 10 to 1000 g ai / ha, preferably 5 to 200 g ai / ha, for example 20, 50, 75, 100 or 200 g ai / ha, typically in combination with component (B) at a ratio of 1 to 5000 g ai / ha, particularly 2 to 2000 g ai / ha, preferably 5 to 200 g ai / ha, for example 30, 60, 100, 250, 500, 800, 1000, 1500 g ai / ha.

[0174] In agricultural practice, the application rate of the composition according to the invention depends on the type of effect desired and is typically in the range of 20 to 4000 g of total composition per hectare.

[0175] When the composition according to the invention is used to treat seeds, a ratio of 0.001 to 50 g of component (A) compound per kg of seeds, preferably 0.01 to 10 g per kg of seeds, and 0.001 to 50 g of component (B) compound per kg of seeds, preferably 0.01 to 10 g per kg of seeds, is generally sufficient.

[0176] To avoid any doubt, when citing references, patent applications, or patents in the text of this application, the full text of the cited references is incorporated herein by reference.

[0177] Examples

[0178] The following examples illustrate the invention. The compounds (and compositions) of the present invention may differ from known compounds (and compositions) in that they have greater potency at lower application rates, which can be demonstrated by those skilled in the art using the experimental procedures outlined in the examples, with lower application rates (if necessary), for example, 50 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm, or 0.2 ppm of one or more active ingredients.

[0179] Throughout this specification, temperatures are given in degrees Celsius (°C) and "mp" indicates melting point. LC / MS refers to liquid chromatography-mass spectrometry, and the apparatus and methods (methods A and B) are described below:

[0180] The LC / MS apparatus and Method A are described as follows:

[0181] SQ detector 2 from Waters

[0182] Ionization method: Electrospray

[0183] Polarity: positive ions and negative ions

[0184] Capillary (kV) 3.0, Cone (V) 30.00, Extractor (V) 2.00, Source Temperature (°C) 150, Desolvation Temperature (°C) 350, Cone Gas Flow Rate (L / Hr) 0, Desolvation Gas Flow Rate (L / Hr) 650

[0185] Quality range: 100 to 900 Da

[0186] DAD wavelength range (nm): 210 to 500

[0187] Method: Waters ACQUITY UPLC, using the following HPLC gradient conditions:

[0188] (Solvent A: Water / Methanol 20:1 + 0.05% Formic Acid and Solvent B: Acetonitrile + 0.05% Formic Acid)

[0189]

[0190] Column type: Waters ACQUITY UPLC HSS T3; Column length: 30 mm; Column inner diameter: 2.1 mm; Particle size: 1.8 micrometers; Temperature: 60℃.

[0191] The LC / MS apparatus and Method B are described as follows:

[0192] SQ detector 2 from Waters

[0193] Ionization method: Electrospray

[0194] Polarity: Positive ion

[0195] Capillary (kV) 3.5, orifice (V) 30.00, extractor (V) 3.00, source temperature (°C) 150, desolvation temperature (°C) 400, orifice gas flow rate (L / Hr) 60, desolvation gas flow rate (L / Hr) 700

[0196] Quality range: 140 to 800 Da

[0197] DAD wavelength range (nm): 210 to 400

[0198] Method: Waters ACQUITY UPLC, using the following HPLC gradient conditions.

[0199] (Solvent A: Water / Methanol 9:1 + 0.1% Formic Acid and Solvent B: Acetonitrile + 0.1% Formic Acid)

[0200]

[0201] Column type: Waters ACQUITY UPLC HSS T3; Column length: 30 mm; Column inner diameter: 2.1 mm; Particle size: 1.8 micrometers; Temperature: 60℃.

[0202] If necessary, the final compound, which is pure in the enantiomeric sense, can be obtained from racemic material via standard physical separation techniques (e.g., reversed-phase chiral chromatography) or via stereoselective synthesis techniques (e.g., by using chiral starting materials).

[0203] A representative description of a chiral analysis apparatus is:

[0204] Supercritical fluid chromatography:

[0205] Waters Acquity UPC 2 / QDa

[0206] PDA detector Waters Acquity UPC 2

[0207] Column: Daicel SFC IC, 3μm, 0.3cm x 10cm, 40℃

[0208] Mobile phase: A: CO2, B: iPr gradient: 0.5% B, within 3.8 min

[0209] ABPR: 1800psi

[0210] Flow rate: 2.0 mL / min

[0211] Detection: 247nm

[0212] Sample concentration: 1 mg / mL, in acetonitrile / isopropanol 50 / 50.

[0213] Injection: 1 μL

[0214] Formulation Examples

[0215]

[0216] The active ingredient is thoroughly mixed with the excipients and the mixture is thoroughly ground in a suitable grinder to provide a wettable powder that can be diluted with water to give a suspension of the desired concentration.

[0217]

[0218] The active ingredient is thoroughly mixed with the adjuvant and the mixture is thoroughly ground in a suitable grinder to provide a powder that can be used directly for seed treatment.

[0219] Emulsifiable concentrates

[0220]

[0221] Emulsions with any required dilution that can be used in plant protection can be obtained by diluting such concentrates with water.

[0222]

[0223] A ready-to-use powder is obtained by mixing the active ingredient with a carrier and grinding the mixture in a suitable grinder. This type of powder can also be used for dry seed dressing.

[0224] Extruder granules

[0225]

[0226] The active ingredient is mixed with the excipients and ground, and the mixture is then moistened with water. The mixture is extruded and then dried in an air stream.

[0227] Coated granules

[0228] Active ingredients [components (A) and (B)] 8%

[0229] Polyethylene glycol (molecular weight 200) 3%

[0230] 89% Kaolin

[0231] The finely ground active ingredient is evenly applied to kaolin clay moistened with polyethylene glycol in a mixer. This process yields dust-free coated granules.

[0232] Suspension concentrates

[0233]

[0234] Finely ground active ingredients are tightly mixed with excipients to obtain a suspension concentrate, from which a suspension concentrate can be diluted with water to obtain a suspension of any desired dilution. Using such dilutions, living plants along with their propagation material can be treated and protected against microbial infection by spraying, pouring, or immersion.

[0235] Flowable concentrates for seed treatment

[0236]

[0237] Finely ground active ingredients are tightly mixed with excipients to obtain a suspension concentrate, from which a suspension concentrate can be diluted with water to obtain a suspension of any desired dilution. Using such dilutions, living plants along with their propagation material can be treated and protected against microbial infection by spraying, pouring, or immersion.

[0238] Slow release capsule suspensions

[0239] A mixture of 28 parts of the active ingredients [components (A) and (B)] was mixed with 2 parts of an aromatic solvent and 7 parts of a toluene diisocyanate / polymethylene-polyphenyl isocyanate mixture (8:1). This mixture was emulsified in a mixture of 1.2 parts of polyvinyl alcohol, 0.05 parts of an antifoaming agent, and 51.6 parts of water until the desired particle size was achieved. 2.8 parts of a 1,6-hexanediamine mixture in 5.3 parts of water was added to this emulsion. The mixture was stirred until polymerization was complete. The resulting capsule suspension was stabilized by adding 0.25 parts of a thickener and 3 parts of a dispersant. This capsule suspension formulation contained 28% of the active ingredient. The diameter of the medium capsule was 8-15 micrometers. The resulting formulation was applied to seeds as an aqueous suspension in a suitable apparatus for this purpose.

[0240] Preparation Examples

[0241] Compounds B.01 to B.15 in Table T1 were prepared using any of the synthetic techniques described in WO 2017 / 055469, WO 2017 / 055473, WO 2017 / 093348, WO 2017 / 118689, WO 2017 / 220485, WO 2018 / 065414, WO 2018 / 158365, WO 2018 / 177894, WO 2018 / 177880, WO 2018 / 219773 and WO 2019 / 002151.

[0242] If necessary, the final compound, which is pure in the enantiomeric sense, can be obtained from racemic material via standard physical separation techniques (e.g., reversed-phase chiral chromatography) or via stereoselective synthesis techniques (e.g., by using chiral starting materials).

[0243] Table T1 : Melting point (mp) data and / or retention time (Rt) data of compounds B.01 to B.15 t ) :

[0244]

[0245]

[0246]

[0247]

[0248]

[0249] Biological Examples

[0250] Example A1: Preventive control of soybean rust fungus (Asian soybean rust fungus) / soybean / leaf disc.

[0251] Four weeks after planting, whole soybean plants were treated with the composition of the described active ingredients. One day after spraying, leaf discs were cut from the first leaf with three leaves. Five replicates were performed at each ratio. One day after treatment, the leaf discs were inoculated with *Potamogeton crispus*. The leaf discs were evaluated 11 to 14 days after inoculation, and bioactivity was derived from the relationship between the treated and untreated test plants. The ratios of active ingredients used are given in g active ingredient (ai) / ha in Tables 1 to 6.

[0252] Results from the tests outlined above are shown in Tables 1 through 6 below. These data indicate that synergistic fungicidal activity against *Dioscorea beanus* rust was observed for the combination of components (A) and (B). Mathematically, according to Colby, the synergistic factor SF corresponds to O / E. In agricultural practice, an SF ≥ 1.0 indicates a significant improvement relative to the additive complementarity of activity (expected activity), while an SF ≤ 0.9 in practical application practices marks a loss of activity compared to the expected activity.

[0253] Table 1: Fungicidal activity against *Potamogeton crispus* in the composition of [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.03) and N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide (B.01).

[0254]

[0255] Table 2: Fungicidal activity against *Potamogeton crispus* in the composition of [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.03) and N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide (B.02) as described in Example A1 above.

[0256]

[0257] Table 3: Fungicidal activity against *Potamogeton crispus* in the composition of [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.03) and N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide (B.03) as described in Example A1 above.

[0258]

[0259]

[0260] Table 4: Fungicidal activity against *Potamogeton crispus* in the composition of [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.03) and 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea (B.04) as described in Example A1 above.

[0261]

[0262] Table 5: Fungicidal activity against *Potamogeton crispus* in the composition of [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.03) and 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea (B.06) as described in Example A1 above.

[0263]

[0264] Table 6: Fungicidal activity against *Potamogeton crispus* in the composition of [(1S,2S)-1-methyl-2-(o-tolyl)propyl](2S)-2-[(4-methoxy-3-propionyloxy-pyridine-2-carbonyl)amino]propionate (A.03) and 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester (B.10).

[0265]

Claims

1. A fungicidal composition comprising a mixture of components (A) and (B) as active ingredients, wherein Component (A) is a compound having formula (I): and Component (B) is selected from the following compounds: N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide, N,2-Dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, N-Ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propionamide, 1-Methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-Ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, or 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylic acid ethyl ester; The weight ratio of component (A) to component (B) ranges from 5:1 to 1:

5.

2. The fungicidal composition according to claim 1, further comprising an additional active ingredient component (C) that is different from component (B) and selected from the group consisting of: metyltetrapole, azoxystrobin, oxadiazon, pyraclostrobin, pyraclostrobin, pyraclostrobin, fenoxystrobin, prothioconazole, cyclophosphamide, difenoconazole, tebuconazole, propiconazole, flutriafol, hexaconazole, chlorfluazuron, tebuconazole, benzo[a]fluoroquinolones, fluopyram, fluopyram, fluopyram, cyclophosphamide, bifenazate, pyraclostrobin, fluopyram, fluopyram, isoflucypram, inpyrfluxam, quinofumelin, ipflufenoq uin, aminopyrifen, fluazinam, fludioxamid, fenpicoxamid, pyridazinamide, benzyl benzoate, butyl morpholine, mancozeb, chlorothalonil, trifluoropyridylamine, Cu-chloride, Cu-hydroxide, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methylformamidinium), N'-[5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methylformamidinium, N'-[5-bromo-2-methyl-6-[(1R)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N- Methyl-formamidinium, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidinium, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidinium, N'-(2-chloro-5-methyl-4-phenoxyphenyl)-N-ethyl-N-methyl-formamidinium, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methyl-formamidinium, N'-[2-chloro-4-(3-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methyl-formamidinium, N'-(2-bromo-5-methyl-4-phenoxy) N'-[2-bromo-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidinium, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-isopropyl-N-methylformamidinium, N'-[4-(2-cyanophenoxy)-2-methyl-5-(trifluoromethyl)phenyl]-N-ethyl-N-methylformamidinium, N'-[5-bromo-2-methyl-4-(2-methylphenoxy)phenyl]-N-ethyl-N-methylformamidinium, N-ethyl-N'-[4-(2-fluorophenoxy)-2-methyl-5-(trifluoromethyl)phenyl]-N-methylformamidinium, (Z,2E)-5-[1-(2,4-Dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamine, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamine, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thio-4H-1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile, 3-[(4-chlorophenyl) Methyl 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)prop-2-ol, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)prop-2-ol, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl] Thiobenzamide, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide, N-[N-methoxy-C-methyl-carbonimide]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2 ... [4-oxadiazol-3-yl]benzamide, N-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]cyclopropanecarboxamide, N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, 1-(5,6-dimethyl-3-pyridyl)-4,4-difluoro-3,3-dimethyl-isoquinoline, and 1-[6-(difluoromethyl)-5-methyl-3-pyridyl]-4,4-difluoro-3,3-dimethyl-isoquinoline.

3. The antifungal composition according to claim 2, wherein, Component (C), which differs from component (B), is a compound selected from the group consisting of: metyltetrapole, azoxystrobin, oxadiazon, azoxystrobin, fenoxystrobin, prothioconazole, cyclophosphamide, difenoconazole, tebuconazole, propiconazole, chlorfluazon, tebuconazole, benzovindiflupyr, fluopyram, fluopyram, pyraclostrobin, inpyrfluxam, fluazinam, pyridabenamide, benzyl benzoate, mancozeb, chlorothalonil, trifluoropyridamole, Cu-chloride, Cu-hydroxide, N'-[5-bromo-2-methyl-6-(1-methyl) ... [5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidinium, N'-[5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidinium, N'-[5-bromo-2-methyl-6-[(1R)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidinium and N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidinium.

4. The antifungal composition according to claim 1, wherein component (B) is N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropaneformamide.

5. The antifungal composition according to any one of claims 1 to 4, wherein, The weight ratio of component (A) to component (B) ranges from 4:1 to 1:

4.

6. The antifungal composition according to any one of claims 1 to 4, wherein, The weight ratio of component (A) to component (B) ranges from 3:1 to 1:

3.

7. The antifungal composition according to any one of claims 1 to 4, wherein, The weight ratio of component (A) to component (B) ranges from 2:1 to 1:

2.

8. The antifungal composition according to any one of claims 1 to 4, wherein, The weight ratio of component (A) to component (B) is 1:

1.

9. The antifungal composition according to any one of claims 1 to 4, wherein, The composition further comprises an agriculturally acceptable carrier and optionally a surfactant.

10. The antifungal composition according to any one of claims 1 to 4, wherein, The composition further comprises a formulation aid.

11. A method for controlling or preventing plant pathogenic fungi on a useful plant, the method comprising applying a fungicidal composition as defined in any one of claims 1 to 10 to the useful plant or its location.

12. A method for controlling or preventing plant pathogenic fungi on the propagation material of a useful plant, the method comprising applying a fungicidal composition as defined in any one of claims 1 to 10 to the propagation material of the useful plant or to the site thereof.

13. The method according to claim 11 or 12, wherein component (A) is applied in combination with component (B) at a ratio of 1 to 5000 g ai / ha at a ratio of 5 to 2000 g ai / ha.

14. The method according to claim 11 or 12, wherein component (A) is applied in combination with component (B) at a ratio of 10 to 1000 g ai / ha to a ratio of 2 to 2000 g ai / ha.

15. The method according to claim 11 or 12, wherein component (A) is applied in combination with component (B) at a ratio of 5 to 200 g ai / ha.

16. Use of the fungicidal composition according to any one of claims 1 to 10, for controlling or preventing rust fungi on soybean plants.

Images